LOS ANGELES, May 23, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC.BB:GNBP), a biotechnology company developing targeted
During his tenure as governor, California became a leader in stem cell research as well as providing the highest levels of funding in the country for cancer and HIV research and treatment. Governor Davis set the most stringent standards for cancer clinical trials and made history by enrolling more children in the federal children's health insurance program (Healthy Families) than any state previously had. He is currently Of Counsel at the Los Angeles office of law firm Loeb & Loeb.
"I believe personalized medicine is the future and holds great promise for those suffering from chronic diseases," stated Governor Davis.
Genesis Biopharma Chairman and CEO, Anthony J. Cataldo, added, "Governor Davis brings tremendous value and insight as a person who has implemented his vision for a better healthcare system through advancements in technology and policy. He offers us his experience in organizational leadership, as well as his knowledge in working with regulatory bodies to help bring our cancer therapies to market to save lives, reduce healthcare costs, and keep America at the forefront of innovative therapeutics."
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Genesis Biopharma, Inc.
Subscribe to our Free Newsletters!